Having dedicated his career to advancing innovative testing tools and treatments for conquering cancer and other debilitating diseases, Alan K. Hauser has 3 decades of experience under his belt encompassing the biotechnical, intellectual property, market, and business aspects of commercializing disruptive drug-discovery and diagnostics platforms, including pioneering microfluidic lab-on-a-chip and DNA microarray systems. With a track record of cross-functional success championing multi-omic Innovation to Commercialization (I2C) by translating promise into practice, Alan has helped launch nine genomic products and build eight bioscience businesses, with company exits exceeding $2 billion. Dr. Hauser’s prior I2C leadership directed toward companion diagnostics (CDx)-stratified precision oncology is particularly relevant as he creates value for Arvetas by charting and executing strategic ROI-led I2C roadmaps and partnering plans for the Company’s proprietary MosaicaTM multiplex spatialomics profiling (MSP) platform. The Arvetas next-generation CDx 2.0 solution holds promise to help oncologists guide treatment decisions by accurately predicting patient response.
Clinical Dx Showcase:
Arvetas is a multiomic spatial profiling company developing next-generation MSP-powered companion diagnostics tests, which, unlike existing low-plex tissue biopsy-based assays, hold tremendous promise to accurately predict clinical outcomes by employing a new class of holistic signatures of a large number of mRNA and protein markers.
Predictive Diagnostics Reimagined - Multiomic Spatial Profiling
Arvetas Biosciences is championing a groundbreaking multiomic spatial profiling (MSP) platform, which, unlike other spatialomic technologies, can simultaneously interrogate a large number of biomarkers (mRNA transcripts and proteins) in clinical tissue with only one round of direct staining and imaging.
Session Abstract – PMWC 2022 Silicon Valley
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative